1

An 8 week randomized Dietary Guidelines for Americans -based diet intervention improves the omega-3 index of healthy women

Christine E. Richardson¹, Sridevi Krishnan^{1,2}, Ira J. Gray^{3,4}, Nancy L. Keim^{1,4}, John W. Newman^{1,3,4,*}

1 - Department of Nutrition, University of California Davis, Davis CA

2 – Department of Pediatrics, School of Medicine, University of California San Diego, San Diego CA

3 - West Coast Metabolomics Center, Genome Center, University of California Davis, Davis CA

4 - USDA-ARS Western Human Nutrition Research Center, Davis CA

Abstract - Background: The Dietary Guidelines for Americans (DGA) recommends consuming >1.75g/wk of long-chain omega-3 fatty acids to reduce the risk of cardiovascular disease (CVD) through triglyceride reduction, however individual responses to treatment vary. *Objective*: We sought to determine if a DGA-conforming diet (DGAD) can increase the omega-3 index (OM3I), a diet-sensitive biomarker of omega-3 fatty acid status, into a health promoting range and reduce fasting triglycerides in 8 weeks. We further explored determinants of the basal OM3I and its response to treatment. *Design*: This is a secondary analysis of a randomized, double-blind 8wk dietary intervention of overweight/obese women fed an 8d rotating DGAD (n =22) or typical American diet (TAD; n =20) registered at www.clinicaltrials.gov as NCT02298725. The DGAD and TAD provided individuals with 16 ± 2 g/wk and 1.2 ± 0.12 g/wk of eisocapentaenoic acid (EPA) + docosahexaenoic acid (DHA), respectively. Habitual diet and body composition were determined at baseline. OM3I, fasting triglycerides, glucose and insulin were measured at 0, 2 and 8wk. *Results:* Baseline OM3I (5.8 ± 1.3 ; n =42) was positively correlated to the dietary (EPA+DHA): dietary fat ratio (p =0.006), negatively correlated to the android fat mass (p =0.0007) and was not different between diet groups. At 8wk, while the TAD-group average OM3I was unchanged (5.8 ± 0.76), the DGAD-group OM3I increased (7.33 ± 1.36 ; p <0.001). In the DGAD-group 9 of 22 (i.e. 41%) participants achieving an OM3I >8%. Subgroup analyses of the DGAD-group revealed that body fat content and distribution influenced the baselinedependent response to treatment. Fasting triglyceride and OM3I changes did not correlate. Conclusions: An 8wk TAD stabilized the OM3I in a healthy range, while a DGAD increased the OM3I into a health-promoting range, but did not reduce fasting triglycerides. Fat distribution and basal omega-3 status are primary factors influencing omega-3 efficacy in overweight/obese women.

*Corresponding author: John W. Newman (john.newman2@usda.gov)

2

Abbreviations: ALA – alpha-linolenic acid; FFQs - Block Food Frequency questionnaires; CVD - cardiovascular disease; Delta-OM3I_(Wk0-8) – 8wk omega 3 index change from baseline; DGA - Dietary Guidelines for Americans; GC-MS - gas chromatography-mass spectrometry; DEXA - dual-energy x-ray absorptiometry; FAME – fatty acid methyl esters; OM3I - omega-3 index; OM3I_(Wk0) – baseline omega 3 index; RBC – red blood cell; SFAT – dietary saturated fat; TAD - typical American diet; TFAT – total dietary fat; TG - triglycerides

3

1 Introduction

2 Cardiovascular disease (CVD) is a leading cause of mortality, accounting for nearly 18 3 million deaths worldwide in 2016 (https://www.who.int/news-room/fact-4 sheets/detail/cardiovascular-diseases-(cvds)). Diet is a modifiable factor that can influence CVD 5 risk. The consumption of the long-chain omega-3 fatty acids eicosapentaenoic acid (EPA) and 6 docosahexaenoic acid (DHA) for CVD risk reduction has received much attention [1, 2]. Various 7 studies have demonstrated the cardioprotective properties of EPA and DHA, with proposed 8 mechanisms including improvements in endothelial function, fasting triglycerides (TG), blood 9 pressure, platelet aggregation, and inflammation [3-10]. Recently, a >3g/d dose of EPA + DHA 10 was suggested as the level required to attain these protections [9]. However, studies have shown 11 inconsistencies in response to omega-3 fatty acid intake, which can be attributed to differences in 12 body weight, gender, age, and genetics, among others [11-13]. 13 Dietary polyunsaturated fatty acids are readily incorporated into cellular phospholipids, 14 and their incorporation into red blood cells (RBCs) combined with the average RBC life span of 15 \sim 115 days provides an accessible and time-integrated measure of dietary fatty acid intake [14, 16 15]. The omega-3 index (OM3I), a metric that expresses the red blood cell EPA + DHA content 17 as a percent of total fatty acids, is a validated diet-sensitive biomarker of tissues omega-3 fatty 18 acid levels [11, 16]. The OM3I reflects a saturable process that responds inversely to the basal 19 status, i.e., upon supplementation, the largest change happens in individuals that start with the 20 lowest values within that population [17]. An OM3I range of 8-12% is associated with reduced 21 CVD risk, while values <4% suggest elevated risk [11, 18]. Therefore, dietary modulation of the 22 OM3I by adherence to a healthful diet with high intermittent doses of omega-3 fatty acid-rich 23 foods may provide an alternative strategy to CVD risk reduction.

4

24	The Dietary Guidelines for Americans (DGA), first published in 1980 and currently
25	modified on a 5y cycle, aim to minimize the risk of developing metabolic diseases such as CVD
26	by focusing on consumption of a healthy, nutrient-dense diet. Accordingly, this intervention
27	study was planned using the 2010 DGAs, which was current at the time, that recommend a diet
28	full of fruits, vegetables, whole grains, low-fat dairy products, and a reduction of sodium, solid
29	fats, and added sugars. It also suggests the consumption of 8oz (i.e. 225g) per week of seafood to
30	consume a daily average of 250mg of eicosapentaenoic acid (EPA) and docosahexaenoic acid
31	(DHA) to enhance the omega-3 fatty acid status of the population [19]. These long-chain omega-
32	3 fatty acids have reported anti-inflammatory and anti-hyperlipidemic properties, and increasing
33	their intake may reduce the risk of cardiometabolic disease [20]. Common interventions
34	assessing impacts on the omega-3 status have included the consumption of EPA + DHA-rich
35	supplements or increasing the consumption of cold-water fatty fish or eggs and poultry raised on
36	DHA-rich diets [21-23]. The dominant form of omega-3 fatty acids consumed in the United
37	States is the essential fatty acid alpha-linolenic acid (ALA) [24]. While increasing the
38	consumption of plant-based foods increases the intake of ALA, due to its low rate of conversion
39	to EPA and DHA, it is generally believed that EPA and DHA consumption are required to
40	meaningfully increase their levels [25]. However, the rate of ALA conversion to EPA can be
41	significant in humans [26-28], despite a high degree of variability influenced by factors including
42	both the absolute [26] and relative [29] amounts of dietary ALA and linoleic acid, exercise [30]
43	and genetic variance in the desaturases and elongases involved in the process [31]. Therefore,
44	while EPA and DHA have a strong acute effect on omega-3 status, ALA-rich diets may
45	themselves influence this outcome. To the best of our knowledge, it is not currently known how
46	following a diet reflecting the DGAs or a typical American diet (TAD) will influence the OM3I

5

within 8 weeks. Moreover, it is unclear if such changes in the OM3I will correlate with changes
in circulating TGs of normo-lipidemic to mildly hyperlipidemic individuals in the same time
frame.

The current report describes a secondary analysis of a clinical intervention in pre-and post-menopausal women evaluating the ability of a 2010 DGA-based diet (DGAD) to beneficially alter the OM3I status and/or plasma TG levels when compared to a typical American diet (TAD) defined as the median intake reported by the Centers for Disease Control and Prevention, National Health and Nutrition Examination Survey. We hypothesize that the DGAD will increase the OM3I status and changes in the OM3I will correlate with changes in plasma TG concentrations.

57

58 Subjects and Methods

59 Study design. The present study used a randomized, double-blind, 8-week dietary intervention in 60 overweight and obese pre-and postmenopausal females registered at www.clinicaltrials.gov as 61 NCT02298725 conducted between Dec 2014 and Mar 2017.A detailed description of the study 62 design has already been published [32, 33]. All procedures were approved by the University of 63 California, Davis (UC Davis), Institutional Review Board. Briefly, volunteers were stratified by 64 menopausal status (pre- or post-) and glucose intolerance (normal compared with insulin 65 resistant), before random assignment in a 1:1 allocation ratio to the DGAD or TAD in blocks of 66 two using Microsoft Office Excel. The study statistician generated the randomization lists using 67 color to indicate treatment, and the principal dietitian assigned the colors to specific diets and 68 implemented the randomization scheme. The randomization schedules were only communicated 69 between the statistician and the dietitian, and the dietitian's assistant was aware of and had

6

70	access to the sequence. Both diets were designed to maintain body weight, to consist of food and
71	beverage items commonly available at grocery stores, and to have a similar appearance. The
72	TAD was based on the 50 th percentile of the NHANES's "What We Eat in America" dietary
73	survey and the DGAD was based on food-group recommendations by the 2010 DGAs. The
74	DGAD consisted of more fruits, vegetables, whole grains, and dairy products, whereas the TAD
75	consisted of more refined grains, solid fats, and added sugars. Eight-day cyclical menus were
76	used, with each day consisting of 3 meals, snacks, and beverages designed to supply adequate
77	calories for participants to maintain their body weight. Menu planning to achieve the estimated
78	experimental differences in omega-3 fatty acid were performed using fatty acid estimates of
79	commercial food products contained in the 2014 version of the Nutrition Data System for
80	Research from the University of Minnesota - Nutrition Coordinating Center
81	(http://www.ncc.umn.edu/products/). All meals were prepared by the Metabolic Kitchen and
82	Human Feeding Laboratory at the USDA - Agricultural Research Service - Western Human
83	Nutrition Research Center and volunteers picked up their meals twice weekly and returned
84	packaging so that compliance could be checked. A more detailed description of the meal
85	preparations, menus, and nutrition composition has been previously published [33]. All analyses
86	were performed in a blinded fashion.
87	

Subjects. Pre- and postmenopausal females (n = 44) aged 20-65 years with a BMI (kg/m²) of 25-39.9 were recruited for this intervention. Sample size was based on the study primary outcome investigating the impact of diet quality on glucose homeostasis in women with at least one risk factor for the metabolic syndrome [33].Sententary women or those with low physical activity levels were recruited with inclusion criteria below the physical activity guidelines of moderate

7

93	activity of 150 min/week, a resting blood pressure of \leq 140/90 mmHg, and if they had 1 or more
94	of the following clinical measures of glucose homeostasis or lipid metabolism: 100-126 mg/dL
95	fasting glucose; 140-199mg/dL oral glucose tolerance test 2-h glucose; Quantitative Insulin
96	Sensitivity Check Index score <0.315 [34]; homeostasis model assessment of insulin resistance
97	(HOMA-IR) >3.67; HbA1c between 5.7-6.5, fasting triglycerides >150mg/dL; high density
98	lipoprotein cholesterol <50mg/dL. Exclusion criteria included: resting blood pressure
99	>140/90mmHg; hemoglobin <11.5g/dL; total cholesterol >300mg/dL; low density lipoprotein
100	cholesterol >189mg/dL; triglycerides >400mg/dL; clinically diagnosed abnormal thyroid or liver
101	function; the presence of any metabolic disease, gastrointestinal disorders, cancer or other
102	serious chronic diseases; pregnancy or lactation; use of tobacco; use of medications for elevated
103	lipids or glucose; regular use of prescription or over-the-counter medications in the 6mo before
104	enrolling into the study; moderate or strenuous physical activity >30 min/d on \geq 5 d/wk; weight
105	change of >5% of body weight in the 6mo before enrolling into the study; working "graveyard"
106	shifts or forced regular all-night wake cycles; dietary restrictions interfering with the intervention
107	foods.
108	
109	Food Frequency Questionnaires: To evaluate the impact of habitual diet on the basal OM3I,
110	dietary intake estimates were assessed using Block Food Frequency questionnaires (FFQs). Each
111	participant completed an FFQ approximately 1 to 2 weeks prior to the initiation of the
112	intervention, and the responses were used to reflect habitual dietary intake.
113	
114	Body Composition: To allow for the analysis of body composition impacts on basal OM3I, the

115 OM3I response to treatment, and as a compounding factor on fasting triglyceride levels, dual-

energy x-ray absorptiometry (DEXA) were performed. Once during baseline (Wk0) and once

116

8

117 during week 8 (Wk8), a whole-body DEXA scan was performed using a Hologic® Discovery[™] 118 ODR® Series 84994 (Hologic, Inc.). This scan provided values for total lean mass, total fat 119 mass, percent body fat, and estimates of gynoid and android fat distribution. 120 121 **Blood collection and clinical chemistry.** Fasting blood samples were collected by a licensed 122 phlebotomist, directly into EDTA containing vacutainers, mixed gently, and centrifuged at 123 1300rcf for 10min at 4°C within 30min of blood collection. After plasma and buffy coat removal, 124 RBCs from a 5mL blood tube were suspended in 14mL phosphate-buffered saline, gently mixed, 125 and pelleted by centrifugation as described above. The washing procedure was repeated and the 126 resulting washed RBCs were transferred to polypropylene Eppendorf tubes and stored at -70°C 127 until analysis. 128 129 *Fatty acid analyses.* To determine dietary fatty acid exposures and assess their impact on red 130 blood cell fatty acid composition, composites of each experimental meal and red blood cell fatty 131 acids were quantified as fatty acids methyl esters (FAMEs) by gas chromatography-mass 132 spectrometry. FAMEs were quantified against authentic standards correcting for methodological 133 recoveries of ~5µmol of d31-tripalmitoylglyceride (Avanti Polar Lipids, Alabaster AL) [35, 36]. 134 Data quality assurance / quality control measures included sample randomization, the inclusion 135 of procedural blanks, duplication of 5% of samples, concurrent analysis of laboratory reference 136 materials in each analytical batch, and the use of isotopically labeled extraction surrogates. 137 Briefly, fatty acids in ~50 mg meal composites or 50 µL of phosphate-buffered saline-138 washed RBCs were extracted with 10:8:11 cylcohexane:isopropanol: 0.1M ammonium acetate in

9

139	the presence of deuterated analytical surrogates [37]. Meal composite and RBC extracted lipid
140	residues were reconstituted in either 1 mL or 200 μ L of 1:1 methanol/toluene (v/v), respectively,
141	and stored at -20°C until derivatization. Isolated lipids were transformed into FAMEs by
142	sequential incubation with methanolic sodium hydroxide and methanolic hydrochloric acid.
143	Specifically, 25 μ L of meal composite extract or 20 μ L of RBC extracts were further diluted
144	with 20µL of 1:1 toluene/methanol (v/v), enriched with 20 µL of 60 µM 10Z-pentadecenoic acid
145	in methanol, diluted with 140 μ L methanol, mixed with 100 μ L of 0.5 M sodium methoxide,
146	headspace flushed with nitrogen and incubated at 60 °C for 1 h. Samples were cooled 5 min
147	before addition of 100 μ L of 3 N methanolic hydrochloric acid, and returned to 60 °C for 30 min.
148	Reaction mixtures were then neutralized with 400 μL potassium carbonate, mixed with 400 μL
149	saturated sodium chloride, and back extracted with 400 μ L hexane.
150	FAMEs were separated on a 30m x 0.25mm, 0.25 μm DB-225ms on 7890B gas
151	chromatograph interfaced with a 5977B mass selective detector (Agilent Technologies) and
152	quantified against 6- to 8-point calibration curves. Calibrants and internal standards were
153	purchased from NuchekPrep (Elysian, MN) or Sigma-Aldrich (St. Louis, MO). Data were
154	acquired and processed with MassHunter v. 3.2. Results were corrected for
155	d31-tripalmitoylglyceride recoveries which were 47 \pm 15% and 49 \pm 12% for meal composites
156	and RBCs, respectively, with derivatization efficiencies of \sim 50%. Replicate precision indicated
157	precision of ~15% for RBC FAMEs above the detection limits and recoveries did not differ by
158	treatment group or time.
159	

160 Statistics: Data normality was assessed using Shapiro-Wilkes tests and Q-Q plots of raw, log,

161 and Johnson transformed data. Johnson transformations were the most robust and used for

10

162 analyses unless indicated. Mean differences were assessed with Student's t-test. Colinear dietary 163 and body composition factors were clustered using an implementation of the VARCLUS 164 algorithm. The influence of physiological parameters and habitual diet on the baseline OM3I 165 were evaluated using linear mixed models alone and together. The minimum set of strong OM3I 166 predictors were generated by stepwise linear regressions with the Bayesian information criterion 167 (BIC) minimization as the stopping function. The influence of diet group and study week on 168 RBC fatty acid composition was assessed using linear mixed models with participant as a random effect with group and week as main effects, followed by adjusted multiple comparison 169 170 tests (Least Square Means Tukey HSD) if main or interaction effects were identified. Pearson's 171 correlations were used to assess correlations in change (wk8-wk0) after adjustement for baseline 172 values. Participants in the DGAD group with the lowest and highest OM3I change were 173 segregated into two magnitude response subgroups using hierarchical cluster analyses of the 0wk 174 to 8wk change in the OM3I (Delta-OM3I_{wk0-8}). Participants were also segregated into OM3I rate 175 of change response subgroups by diet. To this end, K means clustering, the fold-change in the 176 Wk0 to Wk2 OM3I and the 8wk rate of change in the OM3I were used together. All statistical 177 analyses were performed in JMP Pro v 15.1 (SAS Institute, Cary, NC). 178

179 Results

Participant numbers and characteristics: A complete diagram of the enrollment, allocation,
follow-up and analysis is provided in Figure 1. Of the 52 participants enrolled, 44 completed the
intervention without adverse effects. Summarized baseline characteristics of the participants
included in the primary analysis are shown in Table 1, with participant level data provided in
Supplemental Table S1. However, RBC fatty acid results were unavailable for one baseline and

11

185	one terminal blood draw from 2 individuals in the TAD group due to poor analytical
186	performance (n = $2/132$; i.e. 1.5%). Therefore, analyses for the primary outcome of intervention
187	change in OM3I and secondary outcomes investigating the influence of body composition on the
188	change in OM3I and the interaction between OM3I change and fasting triglyceridemia were
189	performed with n =22 for the DGAD and n =20 for the TAD groups. In the DGAD group, a
190	single individual showed inconsistancies between their pre-screening and baseline fasting
191	triglyceride levels, and analyses were performed with and without this subject.
192	
193	Diet and red blood cell fatty acids profiles: The average fatty acid composition of both diet
194	plans are shown in Table 2, while the corresponding average gram amounts delivered in the
195	8-day meal rotations are shown in Table 3 . The individual participant daily intake of each fatty
196	acid is provided in Supplemental Table S2 . These analyses confirmed that the aggregate TAD
197	contained higher saturated fatty acids (SFA) and monounsaturated fatty acids (MUFA) compared
198	to the DGAD (Figure 2A). The TAD also had lower omega-3 polyunsaturated fatty acids (n3-
199	PUFAs), with the relative abundance of n6-PUFAs being equivalent between the two diets. The
200	average daily intake of EPA + DHA for the 8-day menu cycle was 0.18 ± 0.02 and 2.24 ± 0.33
201	g/d for the TAD and DGAD, respectively. However, as can be seen in Figure 2B in the DGAD
202	meal plan, long-chain n3-PUFAs were provided solely in three independent meals on Day 1, Day
203	5, and Day 7 with the EPA + DHA levels of 3.0 ± 0.42 , 2.5 ± 0.37 , and 12 ± 1.7 g/d, or
204	approximately 34 ± 3 , 29 ± 3 and 133 ± 11 mg/kg body wt, respectively in menu day composites.
205	Moreover, both meal plans contained a substantial amount of ALA. The foods providing the

206 majority of omega-3 fatty acids are described in Table 4, and in more detail in Supplemental

12

Table 3. The diet group average RBC fatty acid composition at baseline and after 2 and 8wk of
dietary intervention are shown in Table 5.

209

210 Habitual diet and physiological correlates with baseline OM31: Combined analyses of FFQ in 211 Supplemental Table S4 and baseline body composition data in Supplemental Table S1 using 212 the entire set of completeing subjects (n = 44) identified the estimated dietary EPA + 213 DHA: dietary saturated fat ratio (i.e. (EPA+DHA):SFA) and android fat mass as the strongest 214 predictors of baseline OM3I (OM3I(Wk0)). Variable clustering of FFQ data showed the OM3I to 215 be contained in a cluster with the dietary EPA + DHA, the (EPA+DHA): dietary saturated fat 216 (SFAT) ratio, the (EPA+DHA):total dietary fat (TFAT) ratio, and the MUFA:TFAT ratio. Of 217 these, the (EPA+DHA):SFAT ratio and (EPA+DHA):TFAT ratio were the most strongly 218 correlated with the OM3I(Wk0) (p <0.01) and FFQ estimated EPA + DHA intake was the weakest 219 (p =0.06). Exploring the baseline OM3I correlations with body composition data showed android 220 fat to be negatively correlated and the single best body composition predictor of this status 221 marker ($r^2 = 0.25$, p = 0.0007). Combining dietary and body composition factors into a stepwise 222 linear regression analysis yielded an improved model explaining 43% of the variance in the 223 baseline OM3I ($r^2 = 0.43$, p < 0.0001), which included android fat mass (p = 0.00012) and the 224 (EPA+DHA):SFA ratio (p =0.0018) or (EPA+DHA):TFAT ratio (Supplemental Figure 1). The 225 android fat mass and (EPA+DHA):SFA or (EPA+DHA):TFAT were not correlated (p =0.9). 226

Intervention diet impact on RBC lipids and the OM3I: The fatty acid composition of RBCs was
differentially altered by intervention diets. While no changes in SFAs or MUFAs were observed,
a variety of changes in the PUFAs were noted. In terms of the amount of lipid per mg of RBC,

13

230	DHA was increased by the DGAD ($p = 0.041$) but not TAD ($p = 0.3$). Concentrations of EPA
231	were marginally increased (p = 0.08) and decreased (p = 0.1) by the DGAD and TAD,
232	respectively. When expressed as a mole percent composition, the DGAD group showed increases
233	in EPA and DHA (p <0.0001), and decreases in C22:5n6 (DPA; p =0.012), while the TAD
234	showed a decreased EPA composition (p =0.013), reflected in a 20% reduction in the EPA/DHA
235	relative abundance ($p = 0.0019$). The level of ALA in RBCs was near the analytical detection
236	limit in the assay as applied, and the resulting data were not available for analysis. This is in
237	agreement with reports of RBC ALA content of ~0.1mol% [38].
238	While baseline OM3I of ~5.6 did not differ by group (Table1), at study completion, the
239	DGAD-group OM3I increased to 7.33 ± 1.36 (p<0.001), while the the TAD-group OM3I was
240	unchanged at 5.8 ± 0.76 (p =0.6). As previously reported [17, 21], the baseline omega-3 status
241	influenced the individual response to the intervention. As seen in Figure 3, after 2 weeks of
242	feeding changes in the OM3I were driven by baseline associated interactions in both groups.
243	However, after 8 weeks of feeding, a significant elevation in the OM3I is observed in the
244	DGAD-group, with 21 of 22 (i.e. 95%) participants demonstrating an increase, as opposed to
245	only 30% of the TAD-group.

246

OM3I response subgroup analysis: Despite equivalent dietary omega-3 intake in the DGAD,
substantial variability in the response was observed that were not fully explained by the basal
OM3I status. A cluster analysis of the baseline adjusted 8wk change in the OM3I segregated the
DGAD-group into high and low responsive clusters, while the TAD-group remained as a single
group (Figure 3A). A linear mixed model of the DGAD 8wk change in OM3I

 $252 \qquad (Delta-OM3I_{(Wk0-8)}) \ using \ OM3I_{(Wk0)} \ and \ the \ OM3I \ response \ group, \ revealed \ a \ significant$

14

253	interaction between $OM3I_{(Wk0)}$ and the 8wk Delta-OM3I_{(Wk0-8)} (p = 0.049), with the $OM3I_{(Wk0)}$
254	having a weaker influence in the low reponders. The low responsive group also showed evidence
255	of reduced insulin sensitivity as measured by HOMA-IR ($p = 0.045$), with 8 of 9 low responsive
256	individuals with HOMA-IR scores >2.1, as opposed to only 6 of 13 high responsive individuals.
257	A K-means clustering of the rate of change in the OM3I between 0 and 8wk and the log of the
258	fold-change between wk 0 and 2, identified 3 unique clusters for both the TAD and DGAD
259	groups as shown in Figure 3B. In the DGAD-group, the OM3I increased 1.0 ± 0.5 , 2.6 ± 0.5 ,
260	and 3.4 ± 0.8 in clusters 1, 2, and 3, respectively. In the TAD-group, the average OM3I increased
261	by 0.8 ± 0.3 in cluster 1, remained unchanged (i.e. -0.1 ± 0.3) in cluster 2, and decreased by 1.4 ± 0.3
262	0.6 in cluster 3.
263	
264	Determinants of OM31 change: It has previously been reported that baseline OM3I, body mass,

265 age, sex, and physical activity are strong determinants of the OM3I response to supplementation 266 [12]. Considering the TAD- and DGAD-groups together (n = 42), the baseline OM3I alone 267 explained 34% of the OM3I response (Supplemental Figure 2). However as intervention 268 exposures were significantly different, an analysis by diet was performed. In the TAD group 269 74% of the variance in the Delta-OM3I_(Wk0-8) was explained by negative correlations with the 270 baseline OM3I alone (p <0.0001). In the DGA group only 30% of the variance was explained by 271 the OM3I_(Wk0). Models including OM3I_(Wk0) and the average EPA + DHA daily intake were 272 improved ($r^2 = 0.56$, RMSE = 0.16, p = 0.0004), however, the Delta-OM3I_(Wk0-8) showed a 273 counterintuitive negative correlation with intake (i.e. adjusting for basal status, as dose increased 274 change decreased). A stepwise linear regression built from DEXA-based body composition, BMI 275 and age data accounted for 70% of the variance in the DGAD Delta-OM3I(wk0-8). This false

15

276	discovery rate adjusted standard least squares regression model ($r^2 = 0.70$, RMSE =0.12;
277	p =0.002) included negative associations with the OM3I($wk0$) (p_{adj} =0.027), trunk % fat
278	(p_{adj} =0.012), lean body mass (p_{adj} =0.013) and positive associations with android fat mass
279	$(p_{adj}=0.027)$ and BMI $(p_{adj}=0.033)$. As seen in Figure 4 , the omega-3 fatty acid and body
280	variables condense into four correlated variable clusters. Of these factors, android fat mass is
281	positively correlated with lean body mass, BMI and trunk % fat (p <0.001), along with the
282	average EPA+DHA daily intake. Notably, multidimensional outliers in highly correlated
283	independent variables were not observed. Exploring model factor interactions revealed
284	$OM3I_{(Wk0)}$ interactions with android fat mass (p =0.014), lean mass (p = 0.020) and BMI (p
285	=0.025). Modeling the dose dependent change (i.e. [Delta-OM3I($Wk0-8$)/(EPA+DHA)] and
286	including the OM3I _(Wk0) by android fat interaction improved the model performance ($r^2 = 0.85$;
287	p <0.0001, RMSE = 0.011; Supplemental Figure 3). A boosted tree analysis of the
288	Delta-OM3I($Wk0-8$), also showed the OM3I($Wk0$), along with % body fat, android % fat, and the
289	android:gynoid fat ratio as important explanatory variables (data not shown). These analyses
290	suggest that after adjusting for the basal OM3I status, the omega-3 fatty acid response to dietary
291	EPA+DHA intake is lower as body size increases, but higher as android fat deposition increases.
292	

293 Triglyceride response to OM3I changes: Omega 3 fatty acid intake has been reported to lower 294 circulating triglycerides. The current data set was evaluated for evidence of triglyceride 295 interactions with OM3I status. Changes in triglycerides themselves were inversely related to 296 their baseline levels, and evenly distributed between increases and decreases regardless of the 297 diet intervention group, suggesting a substantial regression to the mean effect with respect to the 298 measured changes in fasting triglycerides (data not shown). Fasting triglyceride levels were not

16

299	directly correlated with the OM3I. In the DGAD-group, changes in the TGs, adjusted for
300	baseline TGs, were positively correlated with changes in the OM3I, adjusted for baseline OM3I
301	(r^2 =0.27, p =0.007). However, removal of a single fasting TG measure, a statistical outlier at
302	baseline in poor agreement with its study pre-screening TG concentration, reduced the strength
303	of this correlation ($r^2 = 0.16$, p = 0.08), although it remained stronger than that seen in the TAD-
304	group ($r^2 = 0.02$, p = 0.6). Analysis of DGAD OM3I response subgroups also showed no
305	association between the OM3I and fasting TGs.
306	
307	Discussion

308 Increasing long-chain omega-3 fatty acid consumption is associated with reductions in 309 lipidomic cardiovascular disease risk factors [39]. The omega-3 index, defined as the sum of the 310 EPA and DHA mole percent relative to the total fatty acid content in RBCs is an established and 311 valuable omega-3 fatty acid status marker [11, 16, 18]. An OM3I between 8-12% appears 312 protective, while a value <4% is associated with increased CVD risk [11, 18]. The present study 313 was established to determine if a diet based on the 2010 DGA can beneficially alter the OM3I 314 and/or blood TG concentrations when compared to a TAD, in pre-and postmenopausal women, 315 within 8 wks. A secondary analysis was performed to evaluate the influence of body composition 316 factors on the responsiveness of the OM3I to dietary omega-3 fatty acid intake.

It has been established that the baseline OM3I is negatively associated with the OM3I response to omega-3 fatty acid intake, and various factors have been reported to influence this status marker. For instance, FFQ-based estimates of the omega-3 fatty acid intake correlate with the OM3I, and an increase in weekly additional servings of fish has been associated with a 6-13% increase in the OM3I [40-43]. Fasting triglyceride levels, age, a history of high cholesterol,

17

322 and smoking have also been reported to influence the OM3I [21-23, 43]. In the current study, the 323 Block FFQ estimated EPA + DHA intake was poorly correlated with the basal OM3I unless 324 expressed as a percentage of the total dietary fat, or its relative abundance with the saturated fat 325 intake. Exploring associations between body composition and the OM3I, android fat mass was 326 found to have a strong negative association with the baseline OM3I, which was independent of 327 the dietary factors. Contradicting this finding, in a previous study of older women, a high dietary 328 omega-3/omega-6 ratio was associated with higher android fat [44]. That study also found that a 329 high dietary SFA/PUFA ratio was positively associated with android fat, a relationship that was 330 weakly observed in the current data (p=0.1). Regardless, elevations in android fat deposition are 331 reportedly associated with elevated plasma triglycerides, endothelial dysfunction, type 2 332 diabetes, and fatty liver disease [45-48], all conditions beneficially affected by high omega-3

333 fatty acid intake.

334 As demonstrated by the diet composition analysis, following the DGA recommendations 335 significantly alters the dietary fat balance relative to a TAD, with elevations in n3-PUFAs and 336 reductions in saturated fats. The DGAD provided ~2.25g/d of EPA+DHA primarily in 3 meals of 337 the 8-day rotating menu. Meals on these days included servings of 80g of salmon or albacore 338 tuna in multiple forms including seafood pasta, a corn and salmon chowder, a salmon dinner, and 339 a seafood salad. In contrast, the TAD provided ~0.25g/d of EPA+DHA. A more detailed 340 description of the meals and there composition has been previously reported [33]. Ultimately, in 341 this sample of overweight/obese women with a mean basal OM3I of \sim 5.6%, 8 weeks of the 342 DGAD increased the OM3I by $1.7 \pm 1.1\%$, while the TAD only reduced it by $-0.15 \pm 0.86\%$, 343 with a final OM3I of $7.4 \pm 1.35\%$ and $5.8 \pm 0.72\%$, respectively. While most individuals on the 344 DGAD showed OM3I improvements of $\sim 1\%$ over the course of the intervention, one person was

18

345 unchanged, and 7 participants had 2.3 - 4.5% change in the OM3I, with 9 exceeding the 346 recommended 8% OM3I by the end of the intervention. Therefore, it is possible to achieve a 347 putatively beneficial OM3I status in 8 weeks by adhering to DGAD recommendations with 348 significant EPA and DHA sources in only 3 meals per week. However, there is significant 349 interindividual variability in response, and rates of improvement slow as the OM3I increases, 350 consistent with previous findings [21, 31]. In mixed models adjusting for the basal OM3I effect, 351 changes in the OM3I were lower as the percent trunk fat and lean body mass increased, but 352 higher as absolute android fat mass and BMI increased. Therefore, it appears that in women with 353 increased abdominal and overall adiposity the omega-3 intervention efficacy was enhanced after 354 adjusting for basal status and body size and android adiposity. However, it is also important to 355 note that women with a low OM3I intervention response also had reduced insulin sensitivity. 356 Considering that men with a higher OM3I were found to have higher insulin sensitivity [49]. 357 these findings bring into question the cause-effect relationship between these factors. In contrast, 358 after the 8wk TAD intervention, the average OM3I of individuals either increased or decreased 359 toward an average OM3I of \sim 5.8%, again with some variability influence primarily by the basal 360 omega-3 fatty acid status. It is unclear if this maintenance of a modest OM3I was due to the low 361 level of EPA+DHA in the diet, or associated with ALA-dependent biosynthesis of EPA. Had this 362 change been purely associated with ALA conversion, an increase in EPA relative to DHA in the 363 TAD group might be expected [26-28]. However, the EPA:DHA ratio was actually reduced in 364 the TAD group at 8wks, suggesting that dietary DHA and/or it biosynthesis in this diet group 365 were sufficient to maintain the OM3I in a neutral range with respect to cardiovascular disease 366 risk.

19

367	Dietary long chain omega-3 fatty acids can have strong hypolipidemic effects in both
368	normal and hyperlipidemic individuals, with these lipid-lowering effects being both dose and
369	time-dependent [9, 39, 50]. For instance, in an 8wk intervention comparing 2 g/d of daily
370	supplements and 2 meals/wk of 250g of trout, both treatments reduced TGs in hyperlipidemic
371	participants [22]. In another effort, 0.85 g/d and 3.4g/d doses of EPA+DHA were compared in a
372	population with a baseline OM3I of $4.46 \pm 1.13\%$. After 8wks of treatment, the OM3I increased
373	to $6.49 \pm 0.21\%$ and $8.79 \pm 0.21\%$, for the low and high doses, respectively. However, only the
374	high dose resulted in TG lowering in the moderately hypertriglyceridemic cohort. Similarly, a
375	weak non-linear association between an increase in the OM3I and a decrease in fasting TG levels
376	was reported in dyslipidemic patients receiving 1.67 g/d of EPA+DHA as fish oil capsules for
377	6mo, with individuals having a change in the OM3I of >4% showing the greatest TG reduction
378	[51]. In the present study of women with a basal OM3I of $5.6 \pm 1.3\%$ and normal to mild
379	hypertriglyceridemia, only weak associations between increasing OM3I and reduced fasting TGs
380	were observed at 8wk in the DGAD group after outlier removal. Therefore, it cannot be
381	concluded from the current data that habitual consumption of a DGAD with elevated ALA and
382	intermittent exposure to substantial dietary EPA + DHA would reduce fasting TG in subjects if
383	maintained for a longer duration.

384

385 Limitations

While foods were purchased in lots to minimize variance in nutritional exposures, measured fatty acids in meal composites were generated at a single time point during the course of the study and the exact dietary exposures may differ from the measured composite meals. Thus omega-3 intake could have varied between participants over the course of the study. The current study has a

20

390	relatively small sample size and includes individuals with a range of normal to mild fasting
391	triglyceridemia, limiting the power to detect hypotriglyceridemic effects. This fact is exacerbated
392	in the reported subgroup analysis. Moreover, genetic factors influencing both long chain omega-
393	3 fatty acid biosynthesis and triglyceridemic responsiveness were not evaluated.
394	
395	Conclusion
396	Adherence to a DGAD with ~16g of EPA+DHA provided in 3 meals/wk for 8wks improves the
397	OM3I status in pre- and post-menopausal women with a basal OM3I of $5.6 \pm 1.3\%$, while an
398	ALA-rich TAD providing 1.4g/wk of EPA+DHA maintained an OM3I of ~6%, which is in the
399	neutral range with respect to CVD risk. While a cardioprotective OM3I of >8% was achieved in
400	40% of participants, no concurrent decreases in fasting TGs were observed in the current
401	timeframe. Notably in women with greater abdominal and overall adiposity the omega-3
402	intervention efficacy was higher after adjusting for basal omega-3 fatty acid status and body size.
403	
404	Acknowledgements
405	This study was supported by the National Dairy Council, Campbell Soup Co., and USDA-ARS
406	Projects 2032-51530-022-00D, 2032-51530-025-00D and 6026-51000-010-05S. The USDA is
407	an equal opportunity provider and employer. The National Dairy Council and Campbell Soup
408	Company did not participate in the final design, implementation, analysis, or interpretation of the
409	data from this study. Campbell Soup provided some bulk foods and associated nutrient
410	information. None of the authors had a conflict of interest to report. We thank our colleagues
411	Sean H. Adams, Lindsay H. Allen, Kevin D. Laugero, and Charles B. Stephenson for their
412	efforts in the study design and execution of the larger study in which the current experiments

21

413	were nested; Dustin Burnett for menu design and production management; Leslie Woodhouse for
414	managing the generation of clinical data; Janet Peerson for guidance and review of statistical
415	analyses. The authors' responsibilities were as follows - JWN and NLK: conceived and
416	developed the research plan; JWN, SK, IJG, and NLK: conducted the research; JWN and IJG:
417	analyzed the data and performed the statistical analysis; CER, JWN: wrote the primary
418	manuscript; SK and NLK: provided significant editorial input of manuscript; all authors: have
419	primary responsibility for final content and read and approved the final manuscript.
420	
421	
422	
423	
424	
425	
426	
427	
428	
429	
430	
431	
432	
433	
434	
435	

2	2
L	L

Variables	Units	TAD	DGAD
n		20	22
Age	у	48.0 ± 10.0	50.7 ± 12.6
OM3I	%	5.98 ± 1.35	5.63 ± 1.27
Fasting TGs	mg/dL	111 ± 49	143 ± 101
HOMA-IR		3.77 ± 2.75	3.22 ± 2.43
BMI	kg/m ²	33.0 ± 3.68	32.0 ± 4.0
Body Weight	kg	88.5 ± 13.8	88.6 ± 15.6
Total Mass _{DEXA} ²	kg	87.0 ± 13.7	86.9 ± 15.3
Lean Mass _{DEXA} ²	kg	47.1 ± 7.1	47.0 ± 8.0
Fat Mass _{DEXA} ²	kg	38.0 ± 7.7	37.8 ± 7.8
Android Fat Mass ²	kg	3.33 ± 0.99	3.48 ± 1.04
Gynoid Fat Mass ²	kg	6.36 ± 1.45	6.37 ± 1.62
Android:Gynoid ²	%	52.1 ± 0.11	56.0 ± 15.1
% Body Fat ²	%	43.2 ± 3.9	43.3 ± 3.0
% Trunk Fat ²	%	44.2 ± 5.3	45.3 ± 3.7

Table 1: Study cohort baseline clinical and body composition characteristics ¹

1- All values are means \pm SD. Group mean differences were not detected by Student's t-tests ($\alpha = 0.05$). DEXA – dualenergy x-ray absorptiometry; DGAD – Dietary Guidelines for Americans diet; OM3I – omega-3 index; TAD – typical American diet; TG – triglycerides.

2- Reported values were derived from DEXA measurements

23

Table 2: Aggre	egate meal composite	e fatty acid compositi	ion (mol%) ¹
Fatty Acid	TAD	DGAD	p-value
C10:0	1.7 ± 0.7	0.90 ± 0.40	0.012
C12:0	3.7 ± 2.1	0.63 ± 0.43	0.0013
C14:0	5.6 ± 1.7	2.8 ± 1.0	0.0013
C15:0	0.39 ± 0.1	0.22 ± 0.07	0.0018
C16:0	24 ± 3	19 ± 4	0.0032
C17:0	0.32 ± 0.07	0.18 ± 0.06	0.0007
C18:0	8.5 ± 0.9	6.7 ± 1.0	0.0021
C19:0	0.025 ± 0.004	0.023 ± 0.005	0.3
C20:0	0.097 ± 0.029	0.11 ± 0.02	0.3
C21:0	0.0035 ± 0.0008	0.0035 ± 0.0007	1
C22:0	0.099 ± 0.082	0.13 ± 0.06	0.4
C24:0	0.046 ± 0.028	0.064 ± 0.024	0.2
C14:1n5	0.43 ± 0.09	0.18 ± 0.09	0.0001
C16:1n7	1.3 ± 0.5	0.90 ± 0.4	0.07
C18:1n9	31 ± 4	39 ± 4	0.0015
C18:1n7	1.6 ± 0.3	2.0 ± 0.4	0.022
C19:1n9	0.0088 ± 0.0049	0.0020 ± 0.003	0.005
C20:1n9	0.072 ± 0.030	0.11 ± 0.07	0.2
C18:2n6	18 ± 5	22 ± 4	0.05
C18:3n6	0.024 ± 0.011	0.025 ± 0.02	0.9
9c,11t-CLA	0.085 ± 0.017	0.036 ± 0.02	0.0001
C20:3n6	0.018 ± 0.0054	0.017 ± 0.009	0.6
C20:4n6	0.087 ± 0.036	0.093 ± 0.049	0.8
C22:4n6	0.019 ± 0.0083	0.020 ± 0.010	0.7
C22:5n6	0.0061 ± 0.0042	0.013 ± 0.010	0.1
C18:3n3	2.0 ± 0.6	3.6 ± 1.2	0.0046
C18:4n3	0.014 ± 0.027	0.05 ± 0.07	0.2
C20:3n3	0.0028 ± 0.0017	0.0076 ± 0.0059	0.046
C20:4n3	0.0017 ± 0.0007	0.0080 ± 0.0100	0.09
C20:5n3	0.0056 ± 0.0083	0.11 ± 0.17	0.1
C22:5n3	0.045 ± 0.012	0.086 ± 0.080	0.2
C22:6n3	0.021 ± 0.006	0.41 ± 0.73	0.2
SFA	45 ± 7	30 ± 6	0.0003
MUFA	35 ± 4	43 ± 4	0.0022
n-6 PUFA	18 ± 5	23 ± 4	0.05
n-3 PUFA	2 ± 1	4 ± 2	0.0023

1 - All values are means \pm SD. Group differences evaluated by Student's t-tests ($\alpha = 0.05$). DGAD – Dietary Guidelines for Americans diet; TAD – typical American diet;

Table 5: Average fatty actu intake (g/o-day rotation)						
Fatty Acid	TAD	DGAD	p-value			
C10:0	18.2 ± 1.8	6.87 ± 0.99	< 0.001			
C12:0	45.3 ± 4.4	5.74 ± 0.83	< 0.001			
C14:0	78.3 ± 7.8	27.6 ± 4	< 0.001			
C15:0	5.89 ± 0.59	2.29 ± 0.33	< 0.001			
C16:0	405 ± 41	208 ± 30	< 0.001			
C17:0	5.69 ± 0.57	2.10 ± 0.3	< 0.001			
C18:0	159 ± 16	83.6 ± 12	< 0.001			
C19:0	0.488 ± 0.049	0.305 ± 0.044	< 0.001			
C20:0	2.09 ± 0.21	1.50 ± 0.22	< 0.001			
C21:0	0.0740 ± 0.0074	0.0500 ± 0.0072	< 0.001			
C22:0	2.42 ± 0.24	2.02 ± 0.29	< 0.001			
C24:0	1.18 ± 0.12	1.03 ± 0.15	< 0.001			
C14:1n5	6.22 ± 0.63	1.82 ± 0.26	< 0.001			
C16:1n7	22.9 ± 2.3	9.89 ± 1.4	< 0.001			
C18:1n9	600 ± 60	494 ± 71	< 0.001			
C18:1n7	29.3 ± 2.9	25.2 ± 3.6	< 0.001			
C19:1n9	0.171 ± 0.017	0.0238 ± 0.0034	< 0.001			
C20:1n9	1.54 ± 0.15	1.45 ± 0.21	0.1			
C18:2n6	341 ± 34	279 ± 41	< 0.001			
C18:3n6	0.453 ± 0.046	0.300 ± 0.044	< 0.001			
9c,11t-CLA	1.55 ± 0.16	0.434 ± 0.062	< 0.001			
C20:3n6	0.366 ± 0.037	0.213 ± 0.030	< 0.001			
C20:4n6	1.77 ± 0.18	1.16 ± 0.17	< 0.001			
C22:4n6	0.423 ± 0.043	0.280 ± 0.041	< 0.001			
C22:5n6	0.140 ± 0.014	0.170 ± 0.025	< 0.001			
C18:3n3	37.6 ± 3.8	45.9 ± 6.7	< 0.001			
C18:4n3	0.243 ± 0.026	0.602 ± 0.088	< 0.001			
C20:3n3	0.0612 ± 0.0061	0.104 ± 0.015	< 0.001			
C20:4n3	0.0336 ± 0.0034	0.106 ± 0.015	< 0.001			
C20:5n3	0.097 ± 0.01	1.36 ± 0.2	< 0.001			
C22:5n3	0.973 ± 0.099	1.21 ± 0.18	< 0.001			
C22:6n3	1.29 ± 0.13	16.6 ± 2.4	< 0.001			
SFA	724 ± 73	341 ± 49	< 0.001			
MUFA	660 ± 66	532 ± 77	< 0.001			
n-6 PUFA	345 ± 35	282 ± 41	< 0.001			
n-3 PUFA	40.3 ± 4.1	65.9 ± 9.6	< 0.001			

Table 3: Average fatty acid intake (g/8-day rotation)¹

1 - All values are means \pm SD. Group differences evaluated by Student's t-tests (α =0.05). DGAD – Dietary Guidelines for Americans diet; TAD – typical American diet

25

I abit	. Amounts of foods providing	- 0.5g	u of ultary ALA, ETA and DITA			
Menu	TAD		DGAD	DGAD		
Day	Food Items	g/d	Food Items	g/d		
1	None		Roasted Potatoes Baked Salmon (1.7g/d) ² Cinnamon Chex	150 80 30		
2	Pizza Crust Mashed Potatoes Ranch Dressing	86 75 30	Roasted Potatoes Stuffing Cinnamon Chex pizza crust Ranch Dressing	150 150 30 86 30		
3	None		Roasted Potatoes Goddess Dressing	150 g 30g		
4	Ranch Dressing	30	Salsa Ranch Dressing Tomato Basil Sauce Tortilla Chips	30 150 30		
5	Breakfast Muffins	65	Cinnamon Apples Baked Salmon (1.7g/d) ² Salsa Ranch Dressing Walnuts	150 80 30 5		
6	Corn-cheddar biscuit Caesar Salad dressing Granola Bars	130 30 37	Roasted Potatoes Corn-cheddar biscuit Ranch Dressing Walnuts	150 65 30 5		
7	Seafood Salad (0.3g/d) ² Mashed Pinto Beans Popcorn Chicken Corn Chips Club Crackers Oreo Cookies	100 60 35 30 28 20	Cinnamon Apples Canned Albacore Tuna (0.7g/d) ² Thousand Island Dressing Walnuts	150 80 30 5		
8	Pancakes Breaded Chicken Patty	150 85	None			

Table 4: Amounts of foods providing >0.3g/d of dietary ALA, EPA and DHA¹

1 - DGAD – Dietary Guidelines for American's diet; TAD – typical American diet

2 - Data in parentheses indicate EPA and DHA content estimated by the Nutrition Data System for Research (v 2014), University of Minnesota Nutrition Coordinating Center (http://www.ncc.umn.edu/products/).

		TAD (n =20)			DGAD (n =22)	
Fatty Acid	Wk 0	Wk 2	Wk 8	Wk 0	Wk 2	Wk 8
C14:0	$1.28\pm0.73~^{\rm AB}$	$1.05\pm1.00^{\rm \ B}$	1.55 ± 1.20 ^A	1.29 ± 0.93	1.11 ± 0.49	0.993 ± 0.66
C15:0	0.387 ± 0.300	0.371 ± 0.074	0.288 ± 0.54	0.346 ± 0.130	0.319 ± 0.082	0.306 ± 0.39
C16:0	29.5 ± 3.8	30.1 ± 3.3	29.8 ± 1.0	28.7 ± 4.1	30.0 ± 3.1	29.7 ± 3.3
C17:0	0.401 ± 0.11	0.362 ± 0.12	0.449 ± 0.34	0.430 ± 0.110	0.356 ± 0.095	0.404 ± 0.15
C18:0	24.2 ± 4.2	23.6 ± 4.1	23.7 ± 6.3	26.0 ± 5.4	24.9 ± 4.6	24.3 ± 5.2
C18:1n9	10.9 ± 1.3	10.7 ± 1.1	10.6 ± 5.5	10.8 ± 1.7	10.7 ± 1.6	10.9 ± 1.7
C18:1n7	2.07 ± 0.38	2.03 ± 0.26	1.92 ± 0.23	1.95 ± 0.65	2.02 ± 0.44	1.98 ± 0.43
C18:2n6	6.52 ± 0.94	6.42 ± 0.90	6.36 ± 6.2	6.31 ± 0.92	5.94 ± 0.73	5.91 ± 0.95
C20:3n6	1.25 ± 0.24	1.28 ± 0.35	1.33 ± 1.6	1.39 ± 0.46	1.42 ± 0.43	1.37 ± 0.19
C20:4n6	9.55 ± 1.4	9.93 ± 1.50	10.1 ± 2.2	9.21 ± 1.3	9.29 ± 1.4	9.22 ± 1.4
C22:4n6	4.06 ± 0.73	4.11 ± 0.83	4.28 ± 0.26	4.22 ± 0.88	4.20 ± 0.85	4.00 ± 0.88
C22:5n6	0.834 ± 0.32	0.877 ± 0.28	0.841 ± 0.23	$0.899\pm0.27~^{ab}$	0.945 ± 0.26 a	0.727 ± 0.3 b
C20:5n3	$0.430 \pm 0.130^{\rm \; A}$	$0.381\pm0.082~^{\rm AB}$	$0.345\pm0.64~^{\rm B}$	$0.383\pm0.15^{\text{ b}}$	$0.422\pm0.13^{\text{ b}}$	0.493 ± 0.18^{a}
C22:5n3	3.14 ± 0.73	3.20 ± 0.84	3.02 ± 1.20	2.90 ± 0.75	2.93 ± 0.59	2.89 ± 0.82
C22:6n3	5.47 ± 1.1	5.57 ± 0.69	5.45 ± 0.46	$5.24\pm0.89^{\:b}$	$5.47 \pm 1.3^{\text{ b}}$	$6.86\pm1.3^{\text{ a}}$
Σ SFA	55.8 ± 3.5	55.5 ± 3.6	55.8 ± 9.5	56.7 ± 4.1	56.7 ± 4.1	55.7 ± 3.9
Σ MUFA	12.9 ± 1.6	12.7 ± 1.3	12.5 ± 1.6	12.7 ± 2.2	12.7 ± 2	12.8 ± 2
Σn-6 PUFA	22.2 ± 2.3	22.6 ± 2.6	22.9 ± 1.2	22.0 ± 2.6	21.8 ± 2.2	21.2 ± 2.6
Σn-3 PUFA	9.04 ± 1.4	9.15 ± 0.79	8.82 ± 1.8	$8.52\pm1.3^{\text{ b}}$	$8.83\pm1.8^{\:b}$	$10.3\pm1.6^{\text{ a}}$
OM3-I	5.90 ± 1.4	5.95 ± 1.2	5.8 ± 0.72	5.63 ± 1.3 ^b	$5.89\pm0.95^{\text{ b}}$	$7.36 \pm 1.4~^{\rm a}$

Table 5: RBC fatty acid mole percent composition ¹

1- All values are means \pm SD. Mean differences for each fatty acid between times within diet groups were assessed by ANOVAs controlling for participant as a random effect and a least squares mean difference Tukey HSD post-hoc tests. For each fatty acid residue, values within diet groups with different superscripts are different at α =0.05. TAD – typical American diet; DGAD – Dietary Guidelines for Americans diet; OM3I – omega-3 index



Figure 1: Study flow diagram documenting participant enrollement, allocation, follow-up and analysis. This diagram conforms the Consolidated Standards of Reporting Trials (i.e. CONSORT). TAD – typical American diet; DGAD - Dietary Guidelines for American's diet; FAMEs – red blood cell fatty acid analysis; QC – quality control criterion.



Figure 2: Fatty acid composition of TAD and DGAD menus. A) Aggregate meal composite fatty acid composition differences between the typical American diet (TAD) and Dietary Guidelines for American's diet (DGAD) menus. Mean composition differences between meal plans are indicated at p <0.001 (**). B) Omega-3 PUFA fatty acid composition in individual meals of the 8-day rotating TAD and DGAD plans. Individual fatty acid residues are displayed if occurring at >0.1 mol% of any meal. Fatty acid mol% composition was determined in duplicate from a single set of meal composities by GC-MS analysis of fatty acid methyl esters.

medRxiv preprint doi: https://doi.org/10.1101/2021.09.22.21263899; this version posted September 23, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.







30





31

References

- 1. Roger, V.L., et al., *Heart disease and stroke statistics-2011 update: a report from the American Heart Association*. Circulation, 2011. **123**(4): p. e18-e209.
- 2. Khan, S.U., et al., *Effect of omega-3 fatty acids on cardiovascular outcomes: A systematic review and meta-analysis.* EClinicalMedicine, 2021.
- 3. Jung, U.J., et al., *n-3 Fatty acids and cardiovascular disease: mechanisms underlying beneficial effects.* Am J Clin Nutr, 2008. **87**(6): p. 2003S-9S.
- 4. Jump, D.B., C.M. Depner, and S. Tripathy, *Omega-3 fatty acid supplementation and cardiovascular disease*. Journal of Lipid Research, 2012. **53**(12): p. 2525-2545.
- 5. Mozaffarian, D. and J.H. Wu, *Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events.* J Am Coll Cardiol, 2011. **58**(20): p. 2047-67.
- 6. Mori, T.A., *Marine OMEGA-3 fatty acids in the prevention of cardiovascular disease.* Fitoterapia, 2017. **123**: p. 51-58.
- 7. Handelsman, Y. and M.D. Shapiro, *Triglycerides, Atherosclerosis, and Cardiovascular Outcome Studies: Focus on Omega-3 Fatty Acids.* Endocr Pract, 2017. **23**(1): p. 100-112.
- 8. McKenney, J.M. and D. Sica, *Role of prescription omega-3 fatty acids in the treatment of hypertriglyceridemia*. Pharmacotherapy, 2007. **27**(5): p. 715-28.
- 9. Skulas-Ray, A.C., et al., Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association. Circulation, 2019. **140**(12): p. e673-e691.
- 10. Backes, J., et al., *The clinical relevance of omega-3 fatty acids in the management of hypertriglyceridemia.* Lipids Health Dis, 2016. **15**(1): p. 118.
- Harris, W.S., L. Del Gobbo, and N.L. Tintle, *The Omega-3 Index and relative risk for* coronary heart disease mortality: Estimation from 10 cohort studies. Atherosclerosis, 2017. 262: p. 51-54.
- 12. Flock, M.R., et al., *Determinants of erythrocyte omega-3 fatty acid content in response to fish oil supplementation: a dose-response randomized controlled trial.* J Am Heart Assoc, 2013. **2**(6): p. e000513.
- 13. Sarter, B., et al., *Blood docosahexaenoic acid and eicosapentaenoic acid in vegans: Associations with age and gender and effects of an algal-derived omega-3 fatty acid supplement.* Clin Nutr, 2015. **34**(2): p. 212-8.
- 14. Dougherty, R.M., et al., *Lipid and phospholipid fatty acid composition of plasma, red blood cells, and platelets and how they are affected by dietary lipids: a study of normal subjects from Italy, Finland, and the USA.* Am J Clin Nutr, 1987. **45**(2): p. 443-55.
- 15. Franco, R.S., *Measurement of red cell lifespan and aging*. Transfus Med Hemother, 2012. **39**(5): p. 302-7.
- 16. Harris, W.S. and C. Von Schacky, *The Omega-3 Index: a new risk factor for death from coronary heart disease?* Prev Med, 2004. **39**(1): p. 212-20.
- 17. Keenan, A.H., et al., *Basal omega-3 fatty acid status affects fatty acid and oxylipin responses to high-dose n3-HUFA in healthy volunteers.* J Lipid Res, 2012. **53**(8): p. 1662-9.
- 18. von Schacky, C., *Omega-3 index and cardiovascular health*. Nutrients, 2014. **6**(2): p. 799-814.

32

- Zhang, Z., et al., Dietary Intakes of EPA and DHA Omega-3 Fatty Acids among US Childbearing-Age and Pregnant Women: An Analysis of NHANES 2001-2014. Nutrients, 2018. 10(4).
- 20. Fazelian, S., et al., *Effect of omega-3 fatty acids supplementation on cardio-metabolic and oxidative stress parameters in patients with chronic kidney disease: a systematic review and meta-analysis.* BMC Nephrol, 2021. **22**(1): p. 160.
- 21. Walker, R.E., et al., *Predicting the effects of supplemental EPA and DHA on the omega-3 index*. Am J Clin Nutr, 2019. **110**(4): p. 1034-1040.
- 22. Zibaeenezhad, M.J., et al., *Comparison of the effect of omega-3 supplements and fresh fish on lipid profile: a randomized, open-labeled trial.* Nutr Diabetes, 2017. **7**(12): p. 1.
- 23. Stanton, A.V., et al., *Omega-3 index and blood pressure responses to eating foods naturally enriched with omega-3 polyunsaturated fatty acids: a randomized controlled trial.* Sci Rep, 2020. **10**(1): p. 15444.
- 24. Papanikolaou, Y., et al., U.S. adults are not meeting recommended levels for fish and omega-3 fatty acid intake: results of an analysis using observational data from NHANES 2003-2008. Nutr J, 2014. **13**: p. 31.
- 25. Arterburn, L.M., E.B. Hall, and H. Oken, *Distribution, interconversion, and dose response of n-3 fatty acids in humans.* Am J Clin Nutr, 2006. **83**(6 Suppl): p. 1467S-1476S.
- 26. Goyens, P.L., et al., *Conversion of alpha-linolenic acid in humans is influenced by the absolute amounts of alpha-linolenic acid and linoleic acid in the diet and not by their ratio.* Am J Clin Nutr, 2006. **84**(1): p. 44-53.
- 27. Brenna, J.T., et al., *alpha-Linolenic acid supplementation and conversion to n-3 long-chain polyunsaturated fatty acids in humans*. Prostaglandins Leukot Essent Fatty Acids, 2009. **80**(2-3): p. 85-91.
- 28. Baker, E.J., et al., *Metabolism and functional effects of plant-derived omega-3 fatty acids in humans.* Prog Lipid Res, 2016. **64**: p. 30-56.
- 29. Harnack, K., G. Andersen, and V. Somoza, *Quantitation of alpha-linolenic acid elongation to eicosapentaenoic and docosahexaenoic acid as affected by the ratio of n6/n3 fatty acids*. Nutr Metab (Lond), 2009. **6**: p. 8.
- 30. Plissonneau, C., et al., *High-Intensity Interval Training and alpha-Linolenic Acid Supplementation Improve DHA Conversion and Increase the Abundance of Gut Mucosa-Associated Oscillospira Bacteria.* Nutrients, 2021. **13**(3).
- 31. Minihane, A.M., *Impact of Genotype on EPA and DHA Status and Responsiveness to Increased Intakes*. Nutrients, 2016. **8**(3): p. 123.
- Krishnan, S., et al., A randomized controlled-feeding trial based on the Dietary Guidelines for Americans on cardiometabolic health indexes. Am J Clin Nutr, 2018. 108(2): p. 266-278.
- 33. Krishnan, S., et al., *Challenges in Designing and Delivering Diets and Assessing Adherence: A Randomized Controlled Trial Evaluating the 2010 Dietary Guidelines for Americans.* Curr Dev Nutr, 2020. 4(3): p. nzaa022.
- 34. Katz, A., et al., *Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans.* J Clin Endocrinol Metab, 2000. **85**(7): p. 2402-10.
- 35. Grapov, D., et al., *Type 2 diabetes associated changes in the plasma non-esterified fatty acids, oxylipins and endocannabinoids.* PLoS One, 2012. **7**(11): p. e48852.

33

- 36. Tepaamorndech, S., et al., *Zinc transporter 7 deficiency affects lipid synthesis in adipocytes by inhibiting insulin-dependent Akt activation and glucose uptake.* FEBS J, 2016. **283**(2): p. 378-94.
- Smedes, F., Determination of total lipid using non-chlorinated solvents. Analyst, 1999.
 124: p. 1711-1718.
- 38. Lemaitre, R.N., et al., *Red blood cell membrane alpha-linolenic acid and the risk of sudden cardiac arrest.* Metabolism, 2009. **58**(4): p. 534-40.
- 39. Burns-Whitmore, B., et al., *Alpha-Linolenic and Linoleic Fatty Acids in the Vegan Diet: Do They Require Dietary Reference Intake/Adequate Intake Special Consideration?* Nutrients, 2019. **11**(10).
- 40. Garneau, V., et al., *Omega-3 fatty acids status in human subjects estimated using a food frequency questionnaire and plasma phospholipids levels.* Nutr J, 2012. **11**: p. 46.
- 41. Ritz, P.P., et al., *Dietary and Biological Assessment of the Omega-3 Status of Collegiate Athletes: A Cross-Sectional Analysis.* PLoS One, 2020. **15**(4): p. e0228834.
- 42. Zhang, A.C. and L.E. Downie, *Preliminary Validation of a Food Frequency Questionnaire to Assess Long-Chain Omega-3 Fatty Acid Intake in Eye Care Practice*. Nutrients, 2019. **11**(4).
- 43. Block, R.C., W.S. Harris, and J.V. Pottala, *Determinants of Blood Cell Omega-3 Fatty Acid Content*. Open Biomark J, 2008. 1: p. 1-6.
- 44. Muka, T., et al., *Dietary fat composition, total body fat and regional body fat distribution in two Caucasian populations of middle-aged and older adult women.* Clin Nutr, 2017. 36(5): p. 1411-1419.
- Alferink, L.J.M., et al., Nonalcoholic Fatty Liver Disease in The Rotterdam Study: About Muscle Mass, Sarcopenia, Fat Mass, and Fat Distribution. J Bone Miner Res, 2019.
 34(7): p. 1254-1263.
- 46. Bouchi, R., et al., *Gender difference in the impact of gynoid and android fat masses on the progression of hepatic steatosis in Japanese patients with type 2 diabetes.* BMC Obes, 2017. **4**: p. 27.
- 47. Kang, S.M., et al., Android fat depot is more closely associated with metabolic syndrome than abdominal visceral fat in elderly people. PLoS One, 2011. 6(11): p. e27694.
- 48. Sari, C.I., et al., Android Fat Deposition and Its Association With Cardiovascular Risk Factors in Overweight Young Males. Front Physiol, 2019. **10**: p. 1162.
- 49. Albert, B.B., et al., *Higher omega-3 index is associated with increased insulin sensitivity and more favourable metabolic profile in middle-aged overweight men.* Sci Rep, 2014. 4: p. 6697.
- 50. Connor, W.E., *Effects of omega-3 fatty acids in hypertriglyceridemic states*. Semin Thromb Hemost, 1988. **14**(3): p. 271-84.
- 51. Skulas-Ray, A.C., et al., *Dose-response effects of omega-3 fatty acids on triglycerides, inflammation, and endothelial function in healthy persons with moderate hypertriglyceridemia.* Am J Clin Nutr, 2011. **93**(2): p. 243-52.